Prescient Therapeutics Ltd has released a press release.
June 2018 Appendix 4C - Quarterly
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Story so far
Earlier from Prescient Therapeutics
- US Patent Granted for PTX-200 for Ovarian Cancer Treatment
- March 2018 Appendix 4C - Quarterly
- Response to Aware Query
- PTX-200 Phase 1b Breast Cancer Trial Results
- March 2018 Investor Presentation
Later from Prescient Therapeutics
- PTX-200 AML Study Expanded
- Appendix 4E and 2018 Annual Report
- Improved manufacturing route for PTX-100
- Change of Registry Address: Automic P/L - Sydney Office
- Pipeline Collaboration for Next Generation Formulations
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics